Marinus Pharmaceuticals, Inc. (MRNS)

1.4400 0.0000 (0.00%) 收市：04:00PM EDT

Marinus Pharmaceuticals, Inc.

5 Radnor Corporate Center
Suite 500 100 Matsonford Road
Radnor, PA 19087
United States
484 801 4670
https://marinuspharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 165

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Scott N. Braunstein M.D.	CEO, President & Chairman	1.01M	無	1963
Mr. Steven E. Pfanstiel C.M.A., M.B.A.	COO, CFO & Treasurer	670.25k	無	1973
Dr. Joseph Hulihan M.D.	Chief Medical Officer	665.47k	無	1957
Dr. Alex Aimetti Ph.D.	Chief Scientific Officer	無	無	無
Ms. Sonya Weigle	Senior VP of Investor Relations, Human Resources & Corporate Affairs	無	無	無
Ms. Martha E. Manning Esq., J. D.	Senior VP, General Counsel & Secretary	無	無	1955
Molly Cameron	Director of Corporate Communications & Investor Relations	無	無	無
Dr. Kimberly A. McCormick Pharm.D.	Chief Regulatory & Quality Assurance Officer	無	無	無
Mr. Thomas J. Lyons	Chief Business Officer	無	無	無
Ms. Christina Shafer	Chief Commercial Officer	無	無	1977

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

公司管治

截至 2024年4月1日 止，Marinus Pharmaceuticals, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：2；董事會：8；股東權利：6；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。